Cite

HARVARD Citation

    Allard, S. et al. (2018). Fetal RHD genotyping is a cost‐effective option for supporting targeted anti‐D prophylaxis in D‐negative pregnancies. BJOG. p. 1423. [Online]. 
  
Back to record